New Delhi, Dec. 10 -- TPG-backed Sai Life Sciences IPO is scheduled to open for subscription tomorrow (Wednesday, December 11).

The firm is a contract research, development, and manufacturing organisation (CRDMO) that focuses on innovation. Backed by the private equity giant TPG Capital, it provides comprehensive services throughout the entire drug discovery, development, and manufacturing process for small-molecule new chemical entities (NCEs) to pharmaceutical and biotechnology companies worldwide.

In the financial year 2024 and for the six-month period ending September 30, 2024, the company served more than 280 and 230 innovator pharmaceutical companies, respectively. This includes 18 of the top 25 pharmaceutical companies by revenue...